BTG plc, the life sciences company, announces that dosing has commenced in a Phase I clinical study of BGC20-0134, a potential treatment for multiple sclerosis.

The randomised, double-blind, placebo-controlled study will assess the pharmacodynamic, pharmacokinetic and safety profiles of single and multiple oral doses of BGC20-0134 in healthy volunteers...........

For the full report please go to MSRC: MS Research News : Drugs : Further Possible MS Drugs and Treatments - http://www.msrc.co.uk/index.cfm?fuseaction=show&pageid=1397